Table 2.
Laboratory findings
| Characteristics | Normal range | All patients | Death | Survivors | P-value |
|---|---|---|---|---|---|
| (n = 671) | (n = 62) | (n = 609) | |||
| Leucocyte counts | 3.5–9.5 ×109/L | 5.8 (4.3–8.2) | 9.6 (7.8–14.0) | 5.2 (3.7–7.0) | <0.001 |
| Neutrophil rate | 40–75 % | 72 (62–84) | 91 (86–93) | 68 (59–76) | <0.001 |
| Lymphocyte rate | 20–50 % | 19 (10–26) | 6 (4–10) | 26 (16–28) | <0.001 |
| Platelet count | 125–350 ×109/L | 210 (155–270) | 153 (75–204) | 215 (172–284) | <0.001 |
| Erythrocyte count | 3.8–5.1 ×1012/L | 4.1 (3.6–4.5) | 4.0 (3.4–4.4) | 4.1 (3.8–4.5) | 0.050 |
| Haemoglobin | 115–150 g/L | 124 (111–135) | 128 (103–140) | 125 (118–135) | 0.545 |
| Alanine aminotransferase | 7–40 U/L | 27 (18–44) | 26 (19–39) | 22 (15–35) | 0.823 |
| Aspartic transaminase | 7–40 U/L | 29 (21–40) | 42 (29–64) | 25 (20–32) | <0.001 |
| Albumin | 40–55 g/L | 36 (33–38) | 33 (30–35) | 37 (35–39) | <0.001 |
| Creatinine | 41–73 μmol/L | 58 (48–70) | 87 (59–160) | 55 (48–63) | <0.001 |
| Creatinine clearance | > 90 mL/min | 97 (88–97) | 67 (35–94) | 99 (92–107) | <0.001 |
| C-reactive protein | < 10 mg/L | 41 (12–81) | 111 (64–191) | 30 (8–59) | <0.001 |
| Procalcitonin | < 0.1 ng/mL | 0.06 (0.04–0.13) | 0.46 (0.14–1.58) | 0.05 (0.03–0.09) | <0.001 |
| CK-MB | 0–5 ng/mL | 0.96 (0.63–1.82) | 3.6 (2.4–6.9) | 0.8 (0.6–1.2) | <0.001 |
| MYO | 0–110 μg/L | 42 (27–85) | 268 (92–768) | 32 (24–63) | <0.001 |
| cTnI* | 0–0.04 ng/mL | 0.006 (0.006–0.016) | 0.235 (0.042–1.996) | 0.006 (0.006–0.011) | <0.001 |
| NT-proBNP | 0–900 pg/mL | 189 (67–494) | 1819 (759–5164) | 132 (58–237) | <0.001 |
CK-MB, creatinine kinase-myocardial band; MYO, myoglobin; cTnI, cardiac troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*
indicated that the proportion of patients with cTnI levels >0.04 ng/mL in all included patients, dead patients, and survivors was 15.8%, 75.8%, and 9.7% on admission, respectively.